Tyrosine kinase inhibitors (TKIs), including sunitinib, pazopanib, axitinib, sorafenib, and cabozanitinib are thought to exert their major therapeutic effects in RCC by antagonism of VEGF receptor (VEGFR) and PDGF receptor (PDGFR), leading to a reduction of tumor angiogenesis. This evidence concerns the gene KDR and renal cell adenocarcinoma.